Frederick R. Appelbaum, MD
Executive Director, Seattle Cancer Care Alliance
Director, Clinical Research Division, Fred Hutchinson Cancer Research Center
Professor, Medical Oncology Division, University of Washington School of Medicine
James O. Armitage, MD
Professor, Internal Medicine
Division of Hematology & Oncology
University of Nebraska
Steven H. Bernstein, MD
Professor, Department of Medicine, Hematology/Oncology (SMD)
James P. Wilmot Cancer Center
University of Rochester Medical Center
Steven E. Coutre, MD
Stanford University School of Medicine
Stephen J. Forman, MD
Chair, Hematology & Hematopoietic Cell Transplantation
City of Hope
Amrita Y. Krishnan, MD
Director, Multiple Myeloma Program
Associate Director, Associate Professor and Physician
Associate Director, Continuing Medical Education
Associate Member, Hematologic Malignancies Program
Comprehensive Cancer Center
City of Hope
Steven T. Rosen, MD
Director, Robert H. Lurie Comprehensive Cancer Center
Jasmine M. Zain, MD
Columbia University Medical Center
New York, NY
Release date: December 30, 2012
Expiration date: December 29, 2013
Estimated time to complete activity: 9.0 Hours
Target Audience This activity has been planned and is intended for hematologists, hematology/oncologists, medical oncologists, radiation oncologists, pathologists, palliative care specialists, oncology nurses and other allied health care professionals who will benefit from a review and update on the latest advances in the diagnosis and treatment of hematologic malignancies.
Statement of Need/Performance Gap Imperative According to the American Cancer Society, it was estimated in 2011 there were 44,600 cases of leukemia, 66,360 cases of non-Hodgkin lymphoma, 8,830 cases of Hodgkin lymphoma, and 20,520 cases of myeloma diagnosed for the first time. An additional 957,900 people are living with or are in remission from those cancers. In addition, the Leukemia and Lymphoma Society estimates that one person is diagnosed with a blood cancer approximately every four minutes in the U.S. Although the death rate for hematologic malignancies has decreased since 2007, approximately 54,000 people this year will die from leukemia, lymphoma and myeloma, which represents nearly 148 people each day, or more than six people every hour.
Treatment options for patients depend on the specific type of cancer, stage of the disease, the speed at which the cancer is growing, and the patient’s overall health. The outcome for patients with hematologic malignancies has dramatically changed with the use of novel therapies. Not only have these agents improved response rates but they have also improved overall survival. The addition of newer agents, however, has different risk implications. Much of what is currently understood about risks in treatment is derived from experience with conventional treatment modalities (e.g., chemotherapy) and may be less clinically relevant.
Heterogeneous in nature, the management of leukemia, lymphoma and multiple myeloma all present complex clinical problems requiring a multidisciplinary approach to diagnosis and treatment. Recognizing that patient quality of life and survival are significantly improved when these cancers are detected early and treated appropriately, there is a need for physicians to remain current on advances in the diagnosis and treatment of these hematologic malignancies.
Given the frequency of their occurrence and the complexities of their individual clinical presentations and courses, there is a need for primary care and specialty physicians to engage in an in-depth examination and discussions of the emerging data that underlie optimal management of these patient populations. Updates in improved curative and palliative treatments, new and improved systemic therapies, and ongoing clinical trials will be profiled and discussed in these series of nine modules.
At the conclusion of this educational initiative, participants should be able to:
Identify potential new treatment options being studied for hematologic malignancies
Evaluate the rationale for new targeted diagnostic and evolving therapeutic strategies used in the care of patients with lymphoma, myeloma, and acute and chronic leukemia
Assess the role and timing of hematopoietic cell transplantation in the management of younger and older patients’ hematologic malignancies
Differentiate the evolving therapeutic strategies for first-line, second-line, third-line, and salvage treatment of hematologic malignancies
Accreditation StatementThis activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of City of Hope and Carden Jennings Publishing Co., Ltd. City of Hope is accredited by the ACCME to provide continuing medical education for physicians.
Credit DeisgnationCity of Hope designates this enduring activity for a maximum of 9.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in each module of the activity.
DisclosureThe City of Hope adheres to ACCME Essential Areas, Standards for Commercial Support, and Policies regarding industry support of continuing medical education. Disclosure of the commercial relationships of everyone in a position to control content of an educational activity will be made at the activity. Speakers are also required to openly disclose discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
The following City of Hope CME Committee members/planners have indicted they have nothing to disclose: Teresa Ball, Kathleen Blazer, MS, EdD, Ina Ervin, Jonathan Espenschied, MD, Karl Gaal, MD, Abigail Wong Grigsby, JD, Jo Hanson, RN, Fouad Kandeel, MD, Patricia Kassab, RN, MS, CTHQ, Lucille Leong, MD, Paul Lin, MD, Mary Mendelsohn, RN, MSN, Robert Morgan, Jr., MD, Anna Pawlowska, MD, I. Benjamin Paz, MD, Crystal Saavedra, BS, Sara Scorcia, Michael Sullivan, MD & Jeffrey Weitzel, MD.
The following CME Committee Members/planners have indicated a conflict with the following corporate organizations:
Ravi Bhatia, MD, discloses that he is a consultant with Novartis and Bristol-Myers Squibb
Martin Hogan, MD, discloses that he received grant/research support from Johnson & Johnson
Laura Brown discloses that she is a stock shareholder with Proctor & Gamble and Johnson & Johnson
Jean Kagan, BA, discloses that she is a stock shareholder with Amgen/Zimmer
Matthew Loscalzo, LSCW discloses that he is a consultant for Novartis and a member of the speakers bureau with Lilly Pharma
Any potential conflicts relative to the previous disclosure have been resolved.
CJP Medical Communications DisclosureThe employees of CJP Medical Communications have no financial relationships to disclose.
Faculty DisclosuresIn accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity.
A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
Frederick R. Appelbaum, MD, discloses that he is a consultant for Celator, Abbott, Cephalon, Pfizer & Igenica
James O. Armitage, MD, discloses that he is a consultant for Ziopharm, Allos, Seattle
Genetics, GSK & Eisai
Steven H. Bernstein, MD, does not have any relevant financial disclosures
Steven E. Coutre, MD, does not have any relevant financial disclosures
Stephen J. Forman, MD, does not have any relevant financial disclosures
Amrita Y. Krishnan, MD, discloses she is a consultant for Celgene & Merck, a member of the speaker’s bureau with Celgene & Millennium, and a stock shareholder with Celgene
Steven T. Rosen, MD, discloses he is a consultant for Teva Pharmaceuticals, Cell Therapeutics, Genzyme,Genentech, Merck, Seattle Genetics & Therakos; he received grant/research support from Amgen, and Avon Center for Excellence, Berlex Laboratories, Biogen Idec, Cytogen Corp, Leukemia & Lymphoma Society, Lynn Sage Cancer & Research Foundation, Millennium & ILEX Partners, NCI, Pharmacyclics Inc, The Coleman Foundation & Wyeth Amyerst Research; he has received honoraria from Plexius Communications, Celgene & Cephalon; he is a member of advisory boards with Abbott Laboratories, MedNet Solutions
Jasmine M. Zain, MD, discloses she is a member of the speaker's bureau with Allos
Therapeutics & Seattle Genetics
Commercial Support This activity has been developed through independent educational grants received from Novartis Pharmaceuticals, Onyx Pharmaceuticals, Otsuka America Pharmaceutical Inc., and Seattle Genetics.
Method of ParticipationThere are no fees for participating in this web-based CME activity. To receive credit during the period December 31, 2012 to December 30, 2013, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, (3) complete the posttests, and (4) complete the activity evaluation form, including the certificate information section.
The posttest can be accessed at the end of the activity modules. Please e-mail any questions to
MediumThe Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.
DisclaimerCarden Jennings Publishing and the City of Hope present this resource for educational purposes only. Participants are expected to use their own expertise and judgment while engaged in the practice of medicine. Please consult full prescribing information for any drugs or procedures discussed within this activity. The views and opinions expressed in these presentations are those of the authors and do not necessarily reflect the views of the co-sponsors, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this publication to ensure accuracy, the authors, City of Hope and Carden Jennings Publishing and their servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this publication, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.
Disclosure of Unlabeled UsesThis reference may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physician’s Desk Reference.
CopyrightAll rights reserved; for personal use only. No part of this presentation may be translated, reproduced or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.
Software RequirementsThe Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser. If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.
If you need to upgrade your Web browser, follow one of the links listed below:
Compatible Web browsers include:
Carden Jennings Publishing collects the information provided by the user. The information is used to provide notification about upcoming programs and educational information that may be of interest to our users. The information is not shared with others for commercial purposes, unless the user has granted prior permission.
Carden Jennings Publishing may collect standard Web traffic data such as the time and date of visit. Carden Jennings Publishing uses this information to administer its Web site. Browsing activity is recorded to form aggregate and anonymous demographic information, which is used as described above. Carden Jennings Publishing does not sell or offer to sell any user data, including registration and billing information, to any third parties for commercial purposes. Carden Jennings Publishing does, when required, provide the minimum subset of information to third parties that are responsible for accreditation and issuance of certification of CME/CE tests submitted. By participating in the Web-based activity, you agree that Carden Jennings Publishing has full permission to provide this minimum subset of information to third parties as required by law.
For CME questions, please contact
or call 626-256-HOPE (4673), Ext. 65622. If you experience technical difficulties, please contact